Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

This study has been completed.
VA Office of Research and Development
Novo Nordisk A/S
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
First received: October 19, 2009
Last updated: April 26, 2012
Last verified: April 2012

October 19, 2009
April 26, 2012
June 2007
February 2010   (final data collection date for primary outcome measure)
Hepatic steatosis measured by magnetic resonance spectroscopy (MRS). [ Time Frame: 3 and 6 months. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00998335 on ClinicalTrials.gov Archive Site
  • Metabolic control as measured by the fasting and postprandial plasma glucose (mixed meal, day-long plasma glucose profile) and A1c. [ Time Frame: 3 and 6 months. ] [ Designated as safety issue: No ]
  • Insulin secretion and insulin sensitivity. [ Time Frame: 3 and 6 months. ] [ Designated as safety issue: No ]
  • Intramyocellular (IMCL) by MRS and visceral fat content by magnetic resonance imaging (MRI). [ Time Frame: 3 and 6 months. ] [ Designated as safety issue: No ]
  • Plasma lipids. [ Time Frame: 3 and 6 months. ] [ Designated as safety issue: No ]
  • Vascular inflammatory markers (hsCRP, ICAM, VCAM, etc.) [ Time Frame: 3 and 6 months. ] [ Designated as safety issue: No ]
  • Anthropometric measures (body weight, body mass index (BMI), total body fat by DXA). [ Time Frame: 3 and 6 months. ] [ Designated as safety issue: No ]
  • Rate of hypoglycemia. [ Time Frame: 6 months. ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes

The optimal insulin therapy in T2DM is controversial and its impact on nonalcoholic fatty liver disease (or NAFLD, a common condition in T2DM; Cusi K, Current Diabetes Reports 2009) has not been systematically studied before, and in particular, never when using the new insulin formulations detemir (Levemir®) or aspart (Novolog®). This study was to determine the effect on hepatic steatosis and insulin secretion/action of lowering the fasting plasma glucose (FPG) to target with once daily basal insulin detemir alone or combining insulin detemir with premeal insulin aspart in patients with uncontrolled type 2 diabetes mellitus (T2DM).

In the first 3 months the investigators will optimize metabolic control in all patients with intensive basal (bedtime) detemir insulin aiming at a normal fasting plasma glucose. After this treatment period, patients will be randomized in the second 3 months in a 2:1 ratio to insulin detemir or detemir plus aspart. The investigators propose that insulin will improve day-long glycemic control and A1c, reduce hepatic steatosis (NAFLD) (primary endpoint) and insulin secretion/sensitivity being well tolerated while causing minimal weight gain and hypoglycemia (secondary endpoints). The study will allow to assess if there is an additional benefit of adding pre-meal rapid-acting insulin aspart to basal insulin to these endpoints.

Clinical studies suggest that control of hyperglycemia in T2DM ameliorates the metabolic abnormalities of T2DM but whether this improves hepatic steatosis has not been examined carefully with the use of improved insulin formulations (i.e, long-acting insulins detemir or glargine, alone or combined with pre-meal short-acting insulins). Most studies have focused on glycemic control without a careful examination to the underlying mechanisms, with some studies reporting on improved hepatic and muscle insulin sensitivity. We have found in our laboratory that intensified insulin therapy in T2DM is associated with enhanced glycogen synthase fractional velocity and non-oxidative glucose disposal, but with no improvement at the level of insulin-stimulated insulin receptor tyrosine phosphorylation, hexokinase II mRNA or enzyme function, phosphatidylinositol 3-kinase (PI 3-kinase) associated with IRS-1, or Akt phosphorylation. Our work did not examine hepatic steatosis or insulin secretion/action, nor was designed to distinguish between the relative contribution of reduced glucotoxicity on insulin sensitivity vs. beta-cell function from pre-meal regular vs. NPH insulin. It is possible that the beneficial effects of insulin therapy of reduced plasma glucose and FFA concentrations may be offset by excessive hyperinsulinemia and weight gain from the use of insulins with suboptimal pharmacokinetics compared to the newer insulin formulations.

Insulin detemir is an insulin analogue approved in 2005 by the FDA. It is a long-acting insulin analogue that has shown to be more predictable in achieving therapeutic plasma insulin levels compared to NPH insulin (see attached articles). This is associated with several clinical benefits, such as better glycemic control, less hypoglycemia, modest weight gain and better quality of life for patients with type 2 diabetes. If gluco-lipotoxicity likely play an important role in the development of hepatic steatosis (NAFLD) in T2DM (as suggested by a growing body of literature, see Cusi K, Current Diabetes Reports 2009) we speculate that if reversed by a strategy of basal long-acting insulin (i.e., insulin detemir) alone, or combined with a rapid-acting analog (i.e., pre-meal insulin aspart) may be a good strategy for the treatment of T2DM. However, the effects of intensive insulin therapy on NAFLD in T2DM (measured by the gold-standard magnetic resonance and spectroscopy or MRS) or on insulin action and insulin secretion using gold-standard metabolic techniques.

Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Type 2 Diabetes
  • Drug: Long-acting bedtime insulin detemir (Levemir)
    Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
    Other Name: Levemir insulin (trademark insulin by Novo Nordisk)
  • Drug: Insulin detemir and pre-meal insulin aspart.
    Insulin detemir at bedtime. Insulin aspart before breakfast, lunch and dinner.
    Other Names:
    • Insulin detemir = Levemir (Novo Nordisk)
    • Insulin aspart = Novolog (Novo Nordisk)
  • Active Comparator: Insulin detemir only
    Patients with uncontrolled T2DM are treated with insulin detemir for 6 months
    Intervention: Drug: Long-acting bedtime insulin detemir (Levemir)
  • Experimental: Insulin detemir plus aspart
    After baseline evaluations (admission #1) insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl. After 3 months patients will be admitted to assess the metabolic effects of intervention. After this, insulin aspart will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose. After another 3 months patients are readmitted and all study procedures repeated as during admissions #1 and #2.
    Intervention: Drug: Insulin detemir and pre-meal insulin aspart.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
February 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

To participate patients must:

  1. Be able to communicate meaningfully with the Investigator and be legally competent to provide written informed consent.
  2. Female patients must be non-lactating and must either be at least two years post-menopausal, or be using adequate contraceptive precautions (i.e. oral contraceptives, approved hormonal implant, intrauterine device, diaphragm with spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy). Female patients who have undergone a hysterectomy are eligible for participation in the study. Female patients (except for those patients who have undergone a hysterectomy or a bilateral oophorectomy) are eligible only if they have a negative pregnancy test throughout the study period.
  3. Age range of 18 to 70 years (inclusive).
  4. Patients must have been on a stable dose of allowed chronic medications for two months prior to entering the double-blind treatment period.
  5. All participants must have the following laboratory values:

    • Hemoglobin ≥ 12 g/dl in males or ≥ 11 g/dl in females
    • Serum creatinine ≤ 1.5 mg/dl
    • AST (SGOT) ≤ 2.5 times upper limit of normal
    • ALT (SGPT) ≤ 2.5 times upper limit of normal
    • Alkaline phosphatase ≤ 2.5 times upper limit of normal

Exclusion Criteria:

Patients will be excluded if any of the following criteria are present:

  1. Individuals with type 1 diabetes or type 2 diabetes and a FPG ≥ 300 mg/dl.
  2. Subjects on sulfonylureas, metformin and/or TZDs unless the dose has been stable for at least 2 months prior to study entry.
  3. Patients on any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on stable doses of such agents for the past two months before entry into the study. Patients may be taking stable doses of estrogens or other hormonal replacement therapy if the patient has been on these agents for the prior two months. Patients taking systemic glucocorticoids will be excluded.
  4. Past (within 1 year) or current history of alcohol abuse.
  5. Patients will be excluded if there is a history of clinically significant heart disease (New York Heart Classification greater than grade II), peripheral vascular disease (history of claudication), or pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation) or chronic renal failure (serum creatinine greater than 1.5 mg/dl).
18 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
The University of Texas Health Science Center at San Antonio
The University of Texas Health Science Center at San Antonio
  • VA Office of Research and Development
  • Novo Nordisk A/S
Principal Investigator: Kenneth Cusi, M.D. The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital
The University of Texas Health Science Center at San Antonio
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP